Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03401788
Title A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Peloton Therapeutics, Inc.
Indications

von Hippel-Lindau disease

renal cell carcinoma

Therapies

Belzutifan

Age Groups: senior | adult
Covered Countries USA | FRA

Additional content available in CKB BOOST